Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: A review of early studies in volunteers

Neurology

Volumn 50, Issue 5 SUPPL. 5, 1998, Pages

  Jorga, Karin M ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3 O METHYLDOPA; BENSERAZIDE; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; DECARBOXYLASE INHIBITOR; LEVODOPA; TOLCAPONE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG TOLERABILITY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUROLOGIC DISEASE; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; URINARY TRACT DISEASE;

EID: 0031949348     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.50.5_suppl_5.s31     Document Type: Article

References (23)

1. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984;7:35-49.
2. Cedarbaum JM. Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Pharmacokinet 1987;13:141-178.
3. Chase TN, Mouradian MM, Engber TM. Motor response complications and the function of striatal efferent systems. Neurology 1993;43(suppl 6):S23-27.
4. Harder S, Baas H, Rietbrock S. Concentration-effect relationship of levodopa in patients with Parkinson's disease. Clin Pharmacokinet 1995;29:243-256.
5. Quinn N, Parkes JD, Marsden CD. Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 1984;34:1131-1136.
6. Shoulson I, Glaubiger GA, Chase TN. On-off response: clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 1975;25:1144-1148.
7. Männistö PT, Ulmanen I, Lundström K, et al. Characteristics of catechol-O-methyl-transferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res 1992;39:291-350.
8. Zürcher G, Keller HH, Kettler R, et al. Ro 40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase: a pharmacological study in rats. Adv Neurol 1990;53:497-503.
9. Zürcher G, Dingemanse J, Da Prada M. Ro 40-7592, a potent inhibitor of extracerebral and brain catechol-O-methyltransferase: preclinical and clinical findings. In: Agnoli A, Campanella G, eds. New developments in therapy of Parkinson's disease. Rome: John Libbey, 1991:37-43.
10. Borgulya J, Da Prada M, Dingemanse J, Scherschlicht R, Schläppi B, Zürcher G. Ro 40-7592: catecholamine-O-methyltransferase (COMT) inhibitor. Drugs Future 1991;16: 719-721.
11. Zürcher G, Dingemanse J, Da Prada M. Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain. Preclinical and clinical findings. Adv Neurol 1993;60:641-647.
12. Maj J, Rogóz Z, Skuza G, Sowinska H, Superata J. Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's disease. J Neural Transm [Park Dis Dement Sect] 1990;2: 101-112.
13. Dingemanse J, Jorga K, Zürcher G, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995;40:253-262.
14. Dingemanse J, Jorga KM, Schmitt M, et al. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 1995;57: 508-517.
15. Dingemanse J, Jorga K, Zürcher G, et al. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol 1996; 50:47-55.
16. Gibaldi M. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1992.
17. Holford NHG, Sheiner LB. Pharmacokinetic and pharmacodynamic modeling in vivo. CRC Crit Rev Bioeng 1981;5:273-322.
18. Floderus Y, Wetterberg L. The inheritance of human erythrocyte catechol-O-methyltransferase activity. Clin Genet 1981; 19:392-395.
19. Spielman RS, Weinshilboum RM. Genetics of red cell COMT activity: analysis of thermal stability and family data. Am J Med Genet 1981;10:279-290.
20. Guldberg HC, Marsden CA. Catechol-O-methyltransferase: pharmacological aspects and physiological role. Pharmacol Rev 1975;27:135-194.
21. Da Prada M, Zürcher G, de Yebenes JG. Ro 40-7592, a potent inhibitor of the COMT in extracerebral tissue and brain: pharmacological studies in rats and monkeys. In: Agnoli A, ed. European Conference on Parkinson's Disease and Extrapyramidal Disorders. Rome: John Libbey, 1990:15.
22. Männistö PT, Tuomainen P, Tuominen RK. Different in vivo properties of three new inhibitors of catechol-O-methyltransferase in the rat. Br J Pharmacol 1992;105:569-574.
23. Törnwall M, Männistö PT. Effects of three types of catechol O-methylation inhibitors on L-3,4-dihydroxyphenylalanine-induced circling behaviour in rats. Eur J Pharmacol 1993;250: 77-84.